Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses

Article Immunology

Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort

Hanna Kann et al.

Summary: The study demonstrates that cross-reactive antibodies can still be detected 12 years after HPV vaccination. Women with high levels of anti-HPV16 antibodies and recipients of the bivalent vaccine show higher rates of cross-reactive seropositivity.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries

Claudia Robles et al.

Summary: The study found that acceptance and completion of the human papillomavirus vaccination program in adult women largely depended on recruitment method, national vaccination program coverage, and personal relationship status. Knowledge of the benefits and safety of the vaccine may be crucial in expanding the target age for vaccination.

AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2021)

Add to Collection

Article Infectious Diseases

Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials

Filipe Colaro Mariz et al.

Summary: This study tracked the data from two international HPV vaccine trials in Finland, and found that HPV vaccine-induced antibodies can last up to 12 years after vaccination. Significant differences were observed in the neutralising antibody efficacy and cross-neutralising antibody efficacy between quadrivalent and bivalent vaccine recipients, which correlated with vaccine efficacy.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial

Matti Lehtinen et al.

Summary: The study findings suggest that HPV vaccination provides type-specific protection against invasive cancer, with 100% efficacy against all HPV-positive cancers during up to 11 years of follow-up.

BMJ OPEN (2021)

Add to Collection

Article Oncology